Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?

Affiliations

• ¹ University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, Australia johannes.alffenaar@sydney.edu.au.
• ² Westmead Hospital, Sydney, Australia.
• ³ Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.
• ⁴ University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands.
• ⁵ University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
• ⁶ Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
• ⁷ Clinical Epidemiology and Medical Statistics Unit, Dept of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
• ⁸ World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Tradate, Italy.
• ⁹ A list of members of the Global Tuberculosis Network Bedaquiline study group can be found in the acknowledgements section.